Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.98
Traws Pharma, Inc. issued 5,982,919 shares of common stock to Institutional and accredited investors for $1.6730 per share for each Purchased Share and accompanying Series A, B, and C Warrants ($1.6630 for Pre-Funded Warrant).
- Security
- common stock
- Shares
- 5,982,919 shares
- Purchaser
- Institutional and accredited investors
- Consideration
- $1.6730 per share for each Purchased Share and accompanying Series A, B, and C Warrants ($1.6630 for Pre-Funded Warrant)
Exact text from the filing
a Phase 2a human challenge trial in the United Kingdom. The purchase price per each Purchased Share and accompanying Series A Warrant, Series B Warrant, and Series C Warrant was $1.6730. The purchase price per each Pre-Funded Warrant and accompanying Series A Warrant, Series B Warrant, and Series C Warrant was $1.6630, and each Pre-Funded Warrant has an exercise
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Traws Pharma, Inc. entered into Purchase Agreement with the purchasers named therein valued at approximately $10,000,000 (effective 2026-04-15).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- the purchasers named therein
- Value
- approximately $10,000,000
- Effective
- 2026-04-15
Exact text from the filing
On April 15, 2026, Traws Pharma, Inc. (the “Company”) announced the pricing of an offering (the “Private Placement”) of an aggregate of (i) 5,982,919 shares (the “Purchased Shares”) of the Company’s common stock, par value $0.01 per share (“Common Stock”) (or, in lieu of Purchased Shares, pre-funded warrants to purchase shares of Common Stock (“Pre-Funded Warrants”)), (ii) Series A warrants to initially purchase up to 5,982,919 shares of Common Stock (the “Series A Warrants”), (iii) Series B warrants to initially purchase up to 5,982,919 shares of Common Stock (the “Series B Warrants”), and (iv) Series C warrants to initially purchase up to 17,948,757 shares of Common Stock (the “Series C Warrants” and together with the Pre-Funded Warrants, the Series A Warrants and the Series B Warrants, the “Warrants”) pursuant to a Securities Purchase Agreement (the “Purchase Agreement”) by and between the Company and the purchasers named therein (the “Investors”).
View on SEC.gov